Skip to main content

Janus Henderson Investors — Portfolio, Page 8

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

227
Companies
$35.8B
Total invested
$153.6M
Avg. check
25
Industries
Biotechnology 20Health Care 10Pharmaceutical 9Therapeutics 9Medical 7Biopharma 7+19 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 169192 of 227
Kailera Therapeutics
October 2025

Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.

Biotechnology · Waltham$600.0M Series B
Biomea Fusion
October 2025

Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.

Biotechnology · Redwood City$25.0M Post Ipo Equity
Star Therapeutics
October 2025

Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.

Health Care · South San Francisco$125.0M Undisclosed
Xos Trucks
September 2025

Xos Trucks specializes in the field of manufacturing fully electric commercial vehicles.

Business Development · Los Angeles$2.4M Post Ipo Equity
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post Ipo Equity
Avidity Biosciences
September 2025

Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.

Biotechnology · San Diego$690.0M Post Ipo Equity
Maze Therapeutics
September 2025

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

Biopharma · South San Francisco$150.0M Post Ipo Equity
Korsana Biosciences
September 2025

Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.

Biopharma · Waltham$150.0M Series A
Compass Therapeutics
August 2025

Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.

Biopharma · Boston$120.0M Post Ipo Equity
Forte Biosciences
June 2025

Forte Biosciences is a biotechnology company that focuses on dermatology.

Biotechnology · Sherman Oaks$75.0M Post Ipo Equity
Heartflow
March 2025

Heartflow is a medical technology company that provides various methods of diagnosis and treatment of cardiovascular disease.

Artificial Intelligence (AI) · Mountain View$98.0M Convertible Note
Arbor Biotechnologies
March 2025

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

Artificial Intelligence (AI) · Cambridge$73.9M Series C
Curevo
March 2025

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

Biopharma · Bothell$110.0M Series B
Claris Biotherapeutics
March 2025

Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.

Biotechnology · Jersey City$5.6M Debt Financing
Wallbox
February 2025

Wallbox is a technology company that provides electric vehicle charging and energy management solutions.

Automotive · Barcelona$15.0M Post Ipo Equity
Aligos Therapeutics
February 2025

Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.

Biotechnology · San Francisco$105.0M Post Ipo Equity
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A
New Amsterdam Pharma
December 2024

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Biotechnology · Naarden$452.6M Post Ipo Equity
Janux Therapeutics
December 2024

Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.

Biotechnology · La Jolla$350.0M Post Ipo Equity
35Pharma
November 2024

35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

Biopharma · Montreal$53.0M Series C
Metsera
November 2024

Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.

Biopharma · New York$215.0M Series B
Neurogene
November 2024

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Biotechnology · New York$200.0M Post Ipo Equity
Alpha-9 Oncology
October 2024

Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.

Biotechnology · Vancouver$175.0M Series C
Aktis Oncology
September 2024

Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.

Biotechnology · Boston$175.0M Series B

Where Janus Henderson Investors invests

Biotechnology20
Health Care10
Pharmaceutical9
Therapeutics9
Medical7
Biopharma7

About Janus Henderson Investors's portfolio

How many companies has Janus Henderson Investors invested in?

Janus Henderson Investors has invested in 227 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Janus Henderson Investors invest in?

Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Medical. The firm invests across 25 different industry categories.

What is Janus Henderson Investors's largest investment?

Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post Ipo Equity round. Janus Henderson Investors's total known invested capital is $35.8B.

What is the average investment size for Janus Henderson Investors?

Janus Henderson Investors's average investment size is $153.6M across its portfolio of 227 companies.

What are Janus Henderson Investors's most recent investments?

Recent Janus Henderson Investors portfolio additions include Kailera Therapeutics, Biomea Fusion, Star Therapeutics, Xos Trucks, Pepgen. These companies were founded in 2020 or later.

Reach the founders behind these 227 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →